[
Anderson, K., Stromnes, I. and Greenberg, P. (2017). Obstacles posed by the tumor microenvironment to T cell activity: A case for synergistic therapies, Cancer Cell 31(3): 311–325.
]Search in Google Scholar
[
Bodnar, M. and Piotrowska, M.J. (2016). Stability analysis of the family of tumour angiogenesis models with distributed time delays, Communications in Nonlinear Science and Numerical Simulation 31(1): 124–142.
]Search in Google Scholar
[
Bodnar, M., Piotrowska, M.J. and Bogdańska, M.U. (2019). Mathematical analysis of a generalised model of chemotherapy for low grade gliomas, Discrete and Continuous Dynamical Systems B 24(5): 2149–2167, DOI: 10.3934/dcdsb.2019088.
]Search in Google Scholar
[
Bodzioch, M., Bajger, P. and Foryś, U. (2021). Angiogenesis and chemotherapy resistance: Optimizing chemotherapy scheduling using mathematical modeling, Journal of Cancer Research and Clinical Oncology 147(8): 2281–2299, DOI: 10.1007/s00432-021-03657-9.
]Search in Google Scholar
[
Brown, C.E., Alizadeh, D., Starr, R., Weng, L., Wagner, J.R., Naranjo, A., Ostberg, J.R., Blanchard, M.S., Kilpatrick, J., Simpson, J., Kurien, A., Priceman, S.J., Wang, X., Harshbarger, T.L., D‘Apuzzo, M., Ressler, J.A., Jensen, M.C., Barish, M.E., Chen, M., Portnow, J., Forman, S.J. and Badie, B. (2016). Regression of glioblastoma after chimeric antigen receptor T-cell therapy, New England Journal of Medicine 375(26): 2561–2569, DOI: 10.1056/NEJMoa1610497.
]Search in Google Scholar
[
Castellarin, M., Watanabe, K., June, C.H., Kloss, C.C. and Posey, A.D. (2018). Driving cars to the clinic for solid tumors, Gene Therapy 25(3): 165–175, DOI: 10.1038/s41434-018-0007-x.
]Search in Google Scholar
[
Colli, P., Gomez, H., Lorenzo, G., Marinoschi, G., Reali, A. and Rocca, E. (2021). Optimal control of cytotoxic and antiangiogenic therapies on prostate cancer growth, Mathematical Models and Methods in Applied Sciences 31(07): 1419–1468, DOI: 10.1142/S0218202521500299.
]Search in Google Scholar
[
D’Agostino, M. and Raje, N. (2020). Anti-BCMA CAR T-cell therapy in multiple myeloma: Can we do better?, Leukemia 34(1): 21–34, DOI: 10.1038/s41375-019-0669-4.
]Search in Google Scholar
[
de Pillis, L., Gu, W., Fister, K., Head, T., Maples, K., Murugan, A., Neal, T. and Yoshida, K. (2007). Chemotherapy for tumors: An analysis of the dynamics and a study of quadratic and linear optimal controls, Mathematical Biosciences 209(1): 292–315,
]Search in Google Scholar
[
D’Errico, G., Machado, H.L. and Sainz Jr., B. (2017). A current perspective on cancer immune therapy: Step-by-step approach to constructing the magic bullet, Clinical and Translational Medicine 6(1): e3, DOI: abs/10.1186/s40169-016-0130-5.
]Search in Google Scholar
[
Feins, S., Kong, W., Williams, E.F., Milone, M.C. and Fraietta, J.A. (2019). An introduction to chimeric antigen receptor (car) T-cell immunotherapy for human cancer, American Journal of Hematology 94(S1): S3–S9, DOI: 10.1002/ajh.25418.
]Search in Google Scholar
[
Foryś, U. and Marciniak-Czochra, A.K. (2003). Logistic equations in tumour growth modelling, International Journal of Applied Mathematics and Computer Science 13(3): 317–325.
]Search in Google Scholar
[
Garcke, H., Lam, K.-F. and Rocca, E. (2018). Optimal control of treatment time in a diffuse interface model of tumor growth, Applied Mathematics & Optimization 78: 495–544, DOI: 10.1007/s00245-017-9414-4.
]Search in Google Scholar
[
Ghorashian, S., Kramer, A., Onuoha, S., Wright, G., Bartram, J., Richardson, R., Albon, S.J., Casanovas-Company, J., Castro, F., Popova, B., Villanueva, K., Yeung, J., Vetharoy, W., Guvenel, A., Wawrzyniecka, P.A., Mekkaoui, L., Cheung, G.W.-K., Pinner, D., Chu, J., Lucchini, G., Silva, J., Ciocarlie, O., Lazareva, A., Inglott, S., Gilmour, K.C., Ahsan, G., Ferrari, M., Manzoor, S., Champion, K., Brooks, T., Lopes, A., Hackshaw, A., Farzaneh, F., Chiesa, R., Rao, K., Bonney, D., Samarasinghe, S., Goulden, N., Vora, A., Veys, P., Hough, R., Wynn, R., Pule, M.A. and Amrolia, P.J. (2019). Enhanced car T cell expansion and prolonged persistence in pediatric patients with all treated with a low-affinity cd19 car, Nature Medicine 25(5): 1408–1414.
]Search in Google Scholar
[
Hege, K.M., Bergsland, E.K., Fisher, G.A., Nemunaitis, J.J., Warren, R.S., McArthur, J.G., Lin, A.A., Schlom, J., June, C.H. and Sherwin, S.A. (2017). Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer, Journal for ImmunoTherapy of Cancer 5(1): 22, DOI: 10.1186/s40425-017-0222-9.
]Search in Google Scholar
[
Koury, J., Lucero, M., Cato, C., Chang, L., Geiger, J., Henry, D., Hernandez, J., Hung, F., Kaur, P., Teskey, G. and Tran, A. (2018). Immunotherapies: Exploiting the immune system for cancer treatment, Journal of Immunology Research 2018: 9585614, DOI: 10.1155/2018/9585614.
]Search in Google Scholar
[
León-Triana, O., Perez-Martinez, A., Ramirez-Orellana, M. and Perez-Garcia, V. (2021). Dual-target CAR-TS with on- and off-tumour activity may override immune suppression in solid cancers: A mathematical proof of concept, Cancers 13(4): 703, DOI: 10.3390/cancers13040703.
]Search in Google Scholar
[
Lima, E.A., Wyde, R., Sorace, A.G. and Yankeelov, T.E. (2022). Optimizing delivery of combination targeted and chemotherapy in a murine model of HER2+ breast cancer, Cancer Research 82(12 Supplement): 5050–5050, DOI: 10.1158/1538-7445.AM2022-5050.
]Search in Google Scholar
[
Locke, F.L., Ghobadi, A., Jacobson, C.A., Miklos, D.B., Lekakis, L.J., Oluwole, O.O., Lin, Y., Braunschweig, I., Hill, B.T., Timmerman, J.M., Deol, A., Reagan, P.M., Stiff, P., Flinn, I.W., Farooq, U., Goy, A., McSweeney, P.A., Munoz, J., Siddiqi, T., Chavez, J.C., Herrera, A.F., Bartlett, N.L., Wiezorek, J.S., Navale, L., Xue, A., Jiang, Y., Bot, A., Rossi, J.M., Kim, J.J., Go, W.Y. and Neelapu, S.S. (2019). Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): A single-arm, multicentre, phase 1-2 trial, The Lancet Oncology 20(1): 31–42.
]Search in Google Scholar
[
Mahlbacher, G.E., Reihmer, K.C. and Frieboes, H.B. (2019). Mathematical modeling of tumor-immune cell interactions, Journal of Theoretical Biology 469: 47–60, DOI: 10.1016/j.jtbi.2019.03.002.
]Search in Google Scholar
[
Maude, S.L., Laetsch, T.W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M.R., Stefanski, H.E., Myers, G.D., Qayed, M., De Moerloose, B., Hiramatsu, H., Schlis, K., Davis, K.L., Martin, P.L., Nemecek, E.R., Yanik, G.A., Peters, C., Baruchel, A., Boissel, N., Mechinaud, F., Balduzzi, A., Krueger, J., June, C. H., Levine, B.L., Wood, P., Taran, T., Leung, M., Mueller, K.T., Zhang, Y., Sen, K., Lebwohl, D., Pulsipher, M.A. and Grupp, S.A. (2018). Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia, New England Journal of Medicine 378(5): 439–448, DOI: 10.1056/NEJMoa1709866.
]Search in Google Scholar
[
Miliotou, N.A. and Papadopoulou, C.L. (2018). CAR T-cell therapy: A new era in cancer immunotherapy, Current Pharmaceutical Biotechnology 19(1): 5–18.
]Search in Google Scholar
[
Mostolizadeh, R., Afsharnezhad, Z. and Marciniak-Czochra, A. (2018). Mathematical model of chimeric anti-gene receptor (CAR) T cell therapy with presence of cytokine, Numerical Algebra, Control and Optimization 8(1): 63–80.
]Search in Google Scholar
[
Pérez-García, V., Calvo, G., Bosque, J., León-Triana, O., Jiménez SĂňchez, J., Pérez Beteta, J., Belmonte-Beitia, J., Valiente, M., Zhu, L., García Gómez, P., Sánchez-Gómez, P., Miguel, E., Hortiguela, R., Azimzade, Y., Molina-García, D., Martínez-Rubio, A., Rojas, A., Ortiz de Mendivil, A., Vallette, F. and Vicente, A. (2020). Universal scaling laws rule explosive growth in human cancers, Nature Physics 16(12): 1–6, DOI: 10.1038/s41567-020-0978-6.
]Search in Google Scholar
[
Pérez-García, V.M. and Pérez-Romasanta, L.A. (2015). Extreme protraction for low-grade gliomas: Theoretical proof of concept of a novel therapeutical strategy, Mathematical Medicine and Biology: A Journal of the IMA 33(3): 253–271, DOI: 10.1093/imammb/dqv017.
]Search in Google Scholar
[
Pozzi, G., Grammatica, B., Chaabane, L., Catucci, M., Mondino, A., Zunino, P. and Ciarletta, P. (2022). T cell therapy against cancer: A predictive diffuse-interface mathematical model informed by pre-clinical studies, Journal of Theoretical Biology 547: 111172, DOI: 10.1016/j.jtbi.2022.111172.
]Search in Google Scholar
[
Radunskaya, A., Kim, R. and Woods, T. (2018). Mathematical modeling of tumor immune interactions: A closer look at the role of a PD-l1 inhibitor in cancer immunotherapy, Spora: A Journal of Biomathematics 4: 25–41, DOI: 10.30707/SPORA4.1Radunskaya.
]Search in Google Scholar
[
Sahoo, P., Yang, X., Abler, D., Maestrini, D., Adhikarla, V., Frankhouser, D., Cho, H., Machuca, V., Wang, D., Barish, M., Gutova, M., Branciamore, S., Brown, C.E. and Rockne, R.C. (2020). Mathematical deconvolution of CAR T-cell proliferation and exhaustion from real-time killing assay data, Journal of The Royal Society Interface 17(162): 20190734, DOI: 10.1098/rsif.2019.0734.
]Search in Google Scholar
[
Sancho-Araiz, A., Mangas-Sanjuan, V. and Trocóniz, I.F. (2021). The role of mathematical models in immuno-oncology: Challenges and future perspectives, Pharmaceutics 13(7): 1016.
]Search in Google Scholar
[
Schuster, S.J., Bishop, M.R., Tam, C.S., Waller, E.K., Borchmann, P., McGuirk, J.P., Jäger, U., Jaglowski, S., Andreadis, C., Westin, J.R., Fleury, I., Bachanova, V., Foley, S.R., Ho, P.J., Mielke, S., Magenau, J.M., Holte, H., Pantano, S., Pacaud, L.B., Awasthi, R., Chu, J., Anak, O., Salles, G. and Maziarz, R.T. (2019). Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma, New England Journal of Medicine 380(1): 45–56, DOI: 10.1056/NEJMoa1804980.
]Search in Google Scholar
[
Shah, N.N. and Fry, T.J. (2019). Mechanisms of resistance to CAR T cell therapy, Nature Reviews Clinical Oncology 16(6): 372–385, DOI: 10.1038/s41571-019-0184-6.
]Search in Google Scholar
[
Stein, A.M., Grupp, S.A., Levine, J.E., Laetsch, T.W., Pulsipher, M.A., Boyer, M.W., August, K.J., Levine, B.L., Tomassian, L., Shah, S., Leung, M., Huang, P.-H., Awasthi, R., Mueller, K.T., Wood, P.A. and June, C.H. (2019). Tisagenlecleucel model-based cellular kinetic analysis of chimeric antigen receptor-T cells, CPT: Pharmacometrics & Systems Pharmacology 8(5): 285–295, DOI: abs/10.1002/psp4.12388.
]Search in Google Scholar
[
Stein, S., Zhao, R., Haeno, H., Vivanco, I. and Michor, F. (2018). Mathematical modeling identifies optimum lapatinib dosing schedules for the treatment of glioblastoma patients, PLOS Computational Biology 14(1): 1–24, DOI: 10.1371/journal.pcbi.1005924.
]Search in Google Scholar
[
Stensjoen, A., Solheim, O., Kvistad, K., Haberg, A., Salvesen, O. and Berntsen, E. (2015). Growth dynamics of untreated glioblastomas in vivo, Neuro-Oncology 17(10): 1402–1411, DOI: 10.1093/neuonc/nov029.
]Search in Google Scholar
[
Świerniak, A., Ledzewicz, U. and Schättler, H. (2003). Optimal control for a class of compartmental models in cancer chemotherapy, International Journal of Applied Mathematics and Computer Science 13(3): 357–368.
]Search in Google Scholar
[
Wang, A.X., Ong, X.J., D’Souza, C., Neeson, P.J. and Zhu, J.J. (2023). Combining chemotherapy with CAR-T cell therapy in treating solid tumors, Frontiers in Immunology 14: 1140541, DOI: 10.3389/fimmu.2023.1140541.
]Search in Google Scholar
[
Yabo, Y.A., Niclou, S.P. and Golebiewska, A. (2021). Cancer cell heterogeneity and plasticity: A paradigm shift in glioblastoma, Neuro-Oncology 24(5): 669–682, DOI: 10.1093/neuonc/noab269.
]Search in Google Scholar
